-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Workforce, Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI) , Diseases
Saturday, December 10, 2022: 4:00 PM-5:30 PM
La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)
Sophie M. Lanzkron, MD, Johns Hopkins School of Medicine
Lanzkron: bluebird bio: Other: Adjudication committee, Research Funding; Novo Nordisk: Other: Adjudication committee; Pfizer: Consultancy, Current equity holder in publicly-traded company; Novartis: Consultancy, Research Funding; Glycomimetics: Consultancy; Imara: Research Funding; GBT: Research Funding; Novartis: Research Funding; Takeda: Research Funding; CSL-behring: Research Funding; HRSA: Research Funding; PCORI: Research Funding; Teva: Current equity holder in publicly-traded company.

Farzana Sayani, MD

Hospital of The University of Pennsylvania, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA

Sana Saif Ur Rehman, MD

Division of Hematology, Washington University School of Medicine, Saint Louis, MO

Monica L. Hulbert, MD

Division of Hematology/ Oncology, Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO